View Item 

Show simple item record

Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry
dc.contributor.authorAbtan, Jérémie
dc.contributor.authorBhatt, Deepak L.
dc.contributor.authorElbez, Yedid
dc.contributor.authorSorbets, Emmanuel
dc.contributor.authorEagle, Kim
dc.contributor.authorReid, Christopher M.
dc.contributor.authorBaumgartner, Iris
dc.contributor.authorWu, David
dc.contributor.authorHanson, Mary E.
dc.contributor.authorHannachi, Hakima
dc.contributor.authorSinghal, Puneet K.
dc.contributor.authorSteg, Philippe Gabriel
dc.contributor.authorDucrocq, Gregory
dc.date.accessioned2017-10-05T18:18:43Z
dc.date.available2018-12-03T15:34:03Zen
dc.date.issued2017-09
dc.identifier.citationAbtan, Jérémie ; Bhatt, Deepak L.; Elbez, Yedid; Sorbets, Emmanuel; Eagle, Kim; Reid, Christopher M.; Baumgartner, Iris; Wu, David; Hanson, Mary E.; Hannachi, Hakima; Singhal, Puneet K.; Steg, Philippe Gabriel; Ducrocq, Gregory (2017). "Geographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry." Clinical Cardiology 40(9): 710-718.
dc.identifier.issn0160-9289
dc.identifier.issn1932-8737
dc.identifier.urihttps://hdl.handle.net/2027.42/138330
dc.publisherWiley Periodicals, Inc.
dc.subject.otherIschemic Risk
dc.subject.otherVorapaxar
dc.subject.otherPeripheral Artery Disease
dc.titleGeographic variation and risk factors for systemic and limb ischemic events in patients with symptomatic peripheral artery disease: Insights from the REACH Registry
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelInternal Medicine and Specialities
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138330/1/clc22721.pdf
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/138330/2/clc22721_am.pdf
dc.identifier.doi10.1002/clc.22721
dc.identifier.sourceClinical Cardiology
dc.identifier.citedreferenceSchwartz GG, Bessac L, Berdan LG, et al. Effect of alirocumab, a monoclonal antibody to PCSK9, on long‐term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014; 168: 682 – 689.
dc.identifier.citedreferenceBartholomew JR, Olin JW. Pathophysiology of peripheral arterial disease and risk factors for its development. Cleve Clin J Med. 2006; 73 ( suppl 4 ): S8 – S14.
dc.identifier.citedreferenceShanmugasundaram M, Ram VK, Luft UC, et al. Peripheral arterial disease—what do we need to know? Clin Cardiol. 2011; 34: 478 – 482.
dc.identifier.citedreferenceBlacher J, Cacoub P, Luizy F, et al. Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. J Vasc Surg. 2006; 44: 314 – 318.
dc.identifier.citedreferenceBlanes JI, Cairols MA, Marrugat J. Prevalence of peripheral artery disease and its associated risk factors in Spain: the ESTIME Study. Int Angiol. 2009; 28: 20 – 25.
dc.identifier.citedreferenceHirsch AT, Criqui MH, Treat‐Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001; 286: 1317 – 1324.
dc.identifier.citedreferenceMakdisse M, Ramos LR, Moreira F, et al. A risk score for predicting peripheral arterial disease in individuals 75 years or older. Arq Bras Cardiol. 2007; 88: 630 – 636.
dc.identifier.citedreferenceCacoub PP, Bhatt DL, Steg PG, et al. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009; 30: 192 – 201.
dc.identifier.citedreferenceAbola MT, Bhatt DL, Duval S, et al. Fate of individuals with ischemic amputations in the REACH Registry: three‐year cardiovascular and limb‐related outcomes. Atherosclerosis. 2012; 221: 527 – 535.
dc.identifier.citedreferenceReiner Z, Catapano AL, De Backer G, et al. ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769 – 1818.
dc.identifier.citedreferenceStone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2014; 63 (25 pt B): 2889 – 2934.
dc.identifier.citedreferenceKumbhani DJ, Steg PG, Cannon CP, et al. Statin therapy and long‐term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J. 2014; 35: 2864 – 2872.
dc.identifier.citedreferenceHayek S, Canepa EF, Sattar A, et al. Effect of ezetimibe on major atherosclerotic disease events and all‐cause mortality. Am J Cardiol. 2013; 111: 532 – 539.
dc.identifier.citedreferenceRobinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1489 – 1499.
dc.identifier.citedreferenceSabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med. 2015; 372: 1500 – 1509.
dc.identifier.citedreferenceSabatine MS, Giugliano RP, Keech A, et al. Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. Am Heart J. 2016; 173: 94 – 101.
dc.identifier.citedreferenceDucrocq G, Bhatt DL, Labreuche J, et al. Geographic differences in outcomes in outpatients with established atherothrombotic disease: results from the REACH Registry. Eur J Prev Cardiol. 2014; 21: 1509 – 1516.
dc.identifier.citedreferenceKatsanos K, Spiliopoulos S, Saha P, et al. Comparative efficacy and safety of different antiplatelet agents for prevention of major cardiovascular events and leg amputations in patients with peripheral arterial disease: a systematic review and network meta‐analysis. PLoS One. 2015; 10:e0135692.
dc.identifier.citedreferenceBhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006; 354: 1706 – 1717.
dc.identifier.citedreferenceBaigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta‐analysis of individual participant data from randomised trials. Lancet. 2009; 373: 1849 – 1860.
dc.identifier.citedreferenceCAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996; 348: 1329 – 1339.
dc.identifier.citedreferenceBhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982 – 1988.
dc.identifier.citedreferenceHiatt WR, Fowkes FG, Heizer G, et al. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017; 376: 32 – 40.
dc.identifier.citedreferencePatel MR, Becker RC, Wojdyla DM, et al. Cardiovascular events in acute coronary syndrome patients with peripheral arterial disease treated with ticagrelor compared with clopidogrel: data from the PLATO Trial. Eur J Prev Cardiol. 2015; 22: 734 – 742.
dc.identifier.citedreferenceBonaca MP, Bhatt DL, Storey RF, et al. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016; 67: 2719 – 2728.
dc.identifier.citedreferenceBonaca MP, Bhatt DL, Cohen M, et al. Long‐term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015; 372: 1791 – 1800.
dc.identifier.citedreferenceMauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug‐eluting stents. N Engl J Med. 2014; 371: 2155 – 2166.
dc.identifier.citedreferenceMorrow DA, Braunwald E, Bonaca MP, et al. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366: 1404 – 1413.
dc.identifier.citedreferenceFowkes FG, Rudan D, Rudan I, et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet. 2013; 382: 1329 – 1340.
dc.identifier.citedreferenceTendera M, Aboyans V, Bartelink ML, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J. 2011; 32: 2851 – 2906.
dc.identifier.citedreferenceVioli F, Basili S, Berger JS, et al. Antiplatelet therapy in peripheral artery disease. Handb Exp Pharmacol. 2012;( 210 ): 547 – 563.
dc.identifier.citedreferenceCriqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992; 326: 381 – 386.
dc.identifier.citedreferenceRothwell PM, Coull AJ, Silver LE, et al. Population‐based study of event‐rate, incidence, case fatality, and mortality for all acute vascular events in all arterial territories (Oxford Vascular Study). Lancet. 2005; 366: 1773 – 1783.
dc.identifier.citedreferenceSteg PG, Bhatt DL, Wilson PW, et al. One‐year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007; 297: 1197 – 1206.
dc.identifier.citedreferenceBhatt DL, Steg PG, Ohman EM, et al. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006; 295: 180 – 189.
dc.identifier.citedreferenceBhatt DL, Eagle KA, Ohman EM, et al. Comparative determinants of 4‐year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. JAMA. 2010; 304: 1350 – 1357.
dc.identifier.citedreferenceCacoub PP, Abola MT, Baumgartner I, et al. Cardiovascular risk factor control and outcomes in peripheral artery disease patients in the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Atherosclerosis. 2009; 204: e86 – e92.
dc.identifier.citedreferenceDucrocq G, Amarenco P, Labreuche J, et al. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation. 2013; 127: 730 – 738.
dc.identifier.citedreferenceOhman EM, Bhatt DL, Steg PG, et al. The REduction of Atherothrombosis for Continued Health (REACH) Registry: an international, prospective, observational investigation in subjects at risk for atherothrombotic events‐study design. Am Heart J. 2006; 151: 786 786.e1 – e10.
dc.identifier.citedreferenceWilson PW, D’Agostino R Sr, Bhatt DL, et al. An international model to predict recurrent cardiovascular disease. Am J Med. 2012; 125: 695 – 703.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
clc22721.pdf
Size:
1.406MB
Format:
PDF
View/Open
Name:
clc22721_am.pdf
Size:
1.068MB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.